• If you are wondering whether Elanco Animal Health's current share price around US$24.75 still offers value, this article walks through what the numbers are saying rather than the headlines.
• The stock has returned 0.3% over the last 7 days, 9.9% over the last 30 days and year to date, and 111.2% over the last year, with a 79.5% return over 3 years and a 13.0% decline over 5 years, which gives mixed signals about how the market has priced it over different time frames.
• Recent coverage of Elanco has focused on how the market is reassessing animal health companies in general, with attention on product pipelines, regulatory milestones, and portfolio reshaping across the sector. This context helps explain why some investors are rethinking both the risks and the potential value attached to ELAN after such strong 1 year and 3 year returns.
• On our checks, Elanco scores a 5/6 valuation score. This suggests most of our tests point to the shares screening as undervalued. Next we will walk through those methods before finishing with a broader way of thinking about valuation that goes beyond a simple scorecard.

Approach 1: Elanco Animal Health Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model looks at the cash Elanco Animal Health is expected to generate in the future and then discounts those projections back to today to estimate what the business might be worth per share.

For Elanco, the model uses a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The company’s last twelve month free cash flow is about $420.9 million. Analyst and extrapolated estimates in the model show projected free cash flow in the mid to late $400 million range over the next decade, with one of the later data points at $878.8 million in 2035.

When those future cash flows are discounted back to today, the model arrives at an estimated intrinsic value of about $34.81 per share. Compared with the current share price around $24.75, this implies the stock is trading at a 28.9% discount, which indicates Elanco appears undervalued on this DCF view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Elanco Animal Health is undervalued by 28.9%. Track this in your watchlist or portfolio, or discover 877 more undervalued stocks based on cash flows.

Approach 2: Elanco Animal Health Price vs Sales

For a company like Elanco that is being assessed on its revenue base rather than current earnings, the P/S ratio is a useful way to gauge how much investors are paying for each dollar of sales. The level of an appropriate P/S ratio is usually influenced by how quickly those sales are expected to grow and how predictable or risky the business is.

Elanco currently trades on a P/S of 2.68x. That sits below both the Pharmaceuticals industry average of 4.61x and a peer group average of 3.41x, which suggests the market is assigning a lower value to its revenues than it does for many comparable companies.

Simply Wall St’s Fair Ratio offers another lens. This is a proprietary estimate of what Elanco’s P/S might be based on factors such as its earnings growth outlook, industry, profit margins, market cap and specific risks. Because it adjusts for these company level traits, it can be more tailored than a simple comparison with peers or an industry average. For Elanco, the Fair Ratio sits at 4.34x, above the current 2.68x, which indicates that the shares screen as undervalued on this metric.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1425 companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your Elanco Animal Health Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives. Narratives let you attach a clear story about Elanco Animal Health to your numbers, such as your view of its fair value and expectations for future revenue, earnings and margins.

A Narrative links three pieces together: the business story you believe, the financial forecast that flows from that story, and the fair value that falls out of those forecasts. This helps you see in one place why you think the shares are attractive or not.

On Simply Wall St, millions of investors can create and explore Narratives on the Community page, compare the Fair Value in each Narrative to the current share price, decide whether the gap is large enough for them to consider buying or selling, and rely on the fact that these Narratives are refreshed when new information such as earnings releases or major news is added to the platform.

For Elanco, one investor might build a Narrative that points to a relatively high fair value based on confidence in its product pipeline and margins, while another might set a much lower fair value if they are more cautious about execution and risks.

Do you think there's more to the story for Elanco Animal Health? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.